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Resumo 
Polifenóis isolados a partir da da romã e do cardo mariano possuem várias propriedades 
farmacológicas como anti-inflamatória, hepatoprotetora, antigenotóxica e anticoagulante. O 
presente estudo foca-se na interação das proteínas PDIA1 e PDIA3 com as substâncias 
polifenólicas punicalagina e silibilina . As proteínas acima mencionadas fazem parte da família de 
proteínas dissulfeto isomerase, envolvidas em várias funções celulares associadas a diferentes 
doenças humanas, concedendo-lhes assim potencial de alvo terapêutico.  
A interação dos polifenóis com a PDIA1 e a PDIA3 foi estudada por fluorescência e técnicas 
calorimétricas e o seu efeito na actividade das proteínas também foi descrito. 
Os dois polifenóis são capazes de se ligar a ambas as proteínas, mas a interação produz 
efeitos diferentes. Isto está ligado ao facto das duas moléculas se ligarem em diferentes sítios nas 
proteínas e à propria conformação das mesmas. Isto faz da punicalagina um inibidor promissor para 
a PDIA3. Ao mesmo tempo, a silibilina, embora não demonstre uma ação inibitória específica, se não 
for limitada à PDIA1, pode ser usada para modular a interação das próprias PDIs com outras 
proteínas de substrato, que estejam envolvidas na formação de complexos macromoleculares 
responsáveis pelas atividades celulares das PDIA1 e PDIA3.  
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Abstract 
Polyphenolic compounds isolated from pomegranate fruit from seed fruits of milk thistle 
possess several pharmacological activities including anti-inflammatory, hepatoprotective, 
antigenotoxic and anticoagulant activities. The present work focuses the attention on PDIA1 and 
PDIA3 interactions with punicalagin and silibinin. PDIA1 and PDIA3, are members of the protein 
disulfide isomerase family involved in several cellular functions, associated with different human 
diseases and it has the potential to be a pharmacological target.  
The interaction of polyphenols with PDIA1 and PDIA3 was explored by fluorescence 
quenching and calorimetric techniques and their effect on the activity of the proteins were 
investigated.  
The two polyphenols are able to bind both proteins but the interaction that is established 
produces different effects. This is certainly connectable to a different site of interaction of the two 
molecules and with the different conformation structure of the proteins themselves. This makes 
punicalagin a promising selective inhibitor for PDIA3. At the same time silibilin, although not showing 
a particular inhibitory action, if not limited towards PDIA1, could be used to modulate the interaction 
of the PDIs themselves with other substrate proteins involved in the formation of macromolecular 
complexes responsible for the cellular activities of the two PDIAs.  
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1. Introduction 
1.1. Protein Disulfide Isomerase family: a member of the thioredoxin 
superfamily  
Thioredoxins (Trx) are small globular proteins that are found in all living cells from 
archeabacteria to humans (Holmgren, 1985). The 3-D structures of Trx proteins are highly 
conserved and are characterized by a central core, consisting of five β-sheets surrounded by four α-helices and their active sites are characterized by the CXXC sequence, also known as the “Trx-
motif” (Fig. 1) (Holmgren, 1995; Martin et al., 1995). This structural configuration is known as 
thioredoxin fold and is present in different protein families, such as protein disulfide isomerases 
(PDIs), in DSB (disulphide bond formation) proteins, in glutaredoxin (Grx), in the glutathione 
reductase and glutathione peroxidase. The structural features that are conserved in Trx family 
members, such as the Trx-fold and the specific primary and secondary structures, lead to a different 
reactivity in catalyzing protein disulfide interchange reactions. It has been shown that both active 
site cysteine residues play an important role in the differentiation of the properties across the family 
and the relative stability (depending on cysteines nucleophilicity) of thiolates determines whether 
these enzymes catalyze oxidation, reduction or isomerization of thiol residues in protein substrates 
(Cheng et al., 2011; Hatahet et al., 2009; Carvalho et al., 2009).  
 
 
Figure 1. The typical Trx-fold. From (Giagamonte, 2019) 
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The protein disulfide isomerase (PDI) proteins with active Trx-domains are generally 
localized in the lumen of the endoplasmic reticulum (ER), where they mediate thiol-disulfide 
interchanges critical during post-translational protein folding (Galligan & Petersen, 2012). This 
family is composed of 21 known proteins in humans, that belong to the thioredoxin superfamily, 
classified by sequence and structural homology (Fig. 2).  
 
 
Figure 2. PDI family members in humans. In blue: catalytic domains a and a’, in green and purple 
non-catalytic b and b’ domains. From: Andreu et al, 2012 
 
These enzymes catalyze the formation, reduction or isomerization of disulfide bonds of 
newly synthesized proteins in the lumen of the endoplasmic reticulum (ER). They are also part of a 
quality-control system, thanks to their molecular chaperone function. These proteins show a 
structural organization with multiple domains; each domain shows the typical Trx-fold and two or 
three of these domains contain the redox-active -CXXC- motif, while the others are considered Trx 
inactive domains (Turano et al., 2002). Because of these redox-inactive domains, PDIs have the 
ability to bind peptides or proteins and to exert a molecular chaperone function (Ferrari et al., 1999; 
Ellgaard et al., 2005). The number, the arrangement of tioredoxin-like domains and the specific 
sequence of the catalytic -CXXC- motif can be used to differentiate the members of this family. 
These differences determine their distinct role in the oxidative folding, but also contribute to their 
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specific functions in other pathways. Furthermore, the differences in their redox active motifs can 
reflect separated roles in oxidation, reduction and isomerization (Kozlov et al., 2006).  
 
1.2. PDIA3 protein  
1.2.1. PDIA3 structure and functions  
PDIA3, also known as ERp57, ERp60, GRP58, and 1,25D3-MARRS, is a prominent member 
of the PDI family that has attracted significant attention by the research community. PDIA3 was first 
detected as a stress-responsive protein with upregulated expression following glucose depletion-
induced cellular stress (Lee et al., 1981). Trx-like domains of the PDI proteins are present as 
catalytically active domains (a or a′) or inactive domains (b or b′). Each domain contains a Trx-like 
fold with alternating α-helices and β-strands (Ferrari et al., 1999; Kozlov et al., 2006; Silvennoinen 
et al., 2004). PDIA3 is structurally similar to PDI, containing four TRX-like domains (a-b-b′-a′), with 
matching redox active CGHC motifs and similar reduction potentials of the enzymes dual catalytic 
domains (Hatahet & Ruddock, 2009; Kozlov et al., 2006).  
The catalytically inactive central domains, b and b′, have a vital role in the specific 
functionality of PDIA3 in protein binding and folding. The N- terminal signal sequence directs initial 
ER localization while the C-terminus contains a QDEL ER retention/retrieval motif (Khanal & 
Nemere, 2007). PDIA3 is classically considered an ER resident protein, but also contains a nuclear 
location sequence. Indeed, there are evidences that the stimulation with various macrophage 
differentiation-inducing agents and cellular stressors is able to induce PDIA3 transfer from 
cytoplasm to nucleus (Grillo et al., 2006; Grindel et al., 2011; Wu et al., 2010). PDIA3 has also been 
detected on cell surface (Khanal & Nemere, 2007), as well as in mitochondria (He et al., 2014; Ozaki 
et al., 2008). Regardless of the mechanism(s) underlying PDIA3's subcellular localization, it is clear 
that the enzyme's activity is not limited to those attributed to classical ER-resident proteins (Fig. 3).  
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Figure 3. Representative PDIA3 cellular localizations and functions. From: Hettinghouse et al, 
2018 
 
1.2.2. PDIA3 localization in the ER  
PDIA3 is mainly located in the ER, where it participates to the correct folding and to 
the quality control of neo-synthesized glycoproteins destined to be secreted or localized to 
the cell membrane. To do this, PDIA3 interacts with lectins calreticulin (CRT) or calnexin 
(CNX), which are responsible for recognizing and binding to monoglycosylated proteins 
(Oliver et al., 1997; Molinari et al., 1999; Oliver et al., 1999).  
It has been reported that modifications of specific residues in the b’ domain of PDIA3 
reduce or abolish its binding to calreticulin, indicating that this domain is responsible for this 
interaction (Russell et al., 2004). PDIA3, in complex with CRT/CNX, performs disulfide 
shuffling, a process that requires the intermediate formation of a mixed disulfide between 
the glycoprotein and the proximal cysteine of one of the two active sites of PDIA3. The 
shuffling is then completed by the intervention of the distal cysteine present in the same 
active site. A second important function of PDIA3 in the ER is the participation in the 
assembly of the major histocompatibility complex (MHC) class I (Lindquist e al., 1998). An 
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efficient antigen processing through the MHC I requires the formation of the peptide-
loading complex (PLC). This complex consists of the transporter associated with antigen 
processing (TAP) as centerpiece, which recruits the major histocompatibility complex class 
I (MHC I) heavy-chain/β2-microglobulin dimer by the adapter protein tapasin (Tsn). The 
transient Tsn-MHC I interaction is stabilized by PDIA3, and the endoplasmic reticulum (ER) 
chaperone calreticulin (CRT), which recognizes the monoglucose unit of N-core 
glycosylated MHC I molecules.  
In the PLC, PDIA3 interacts with tapasin (Dick et al., 2002); the structure of this 
complex has been resolved at 2.6 A ̊ resolution (Dong et al., 2009); this was the first time in 
which the completely 3D structure of PDIA3 was obtained. Both a and a' domains of PDIA3 
are involved in the interaction with tapasin. The cysteine 57 in the domain of PDIA3 forms a 
disulfide bond with cysteine 95 of tapasin, while the a' domain-tapasin interaction is entirely 
non-covalent. The tapasin-PDIA3 complex is essential in the assembly and the stabilization 
of the PLC where PDIA3 shows a structural role rather than a catalytic one. In fact, the 
suppression of PDIA3 affects the stability of PLC and decreases both the expression of 
MHC I on the cell surface and the peptide loading within the PLC (Garbi et al., 2006). PDIA3 
also modulates the activity of the sarco/endoplasmic reticulum calcium ATPase (SERCA), 
a Ca2+-ATPase that transfers Ca2+ from the cytosol to the lumen of the ER, by regulating the 
redox state of the sulfhydryl groups in the intraluminal domain of SERCA (Li et al., 2004).  
 
1.2.3. PDIA3 localization in the cytosol  
PDIA3 has been reported in the cytosol thanks to its interaction with other proteins. In this 
localization, it associates with STAT3 (Sehgal, 2003). STAT3 is a member of the STAT (Signal 
Transducer and Activator of Transcription) family. In response to cytokines and growth factors, 
these proteins are phosphorylated by receptor-associated kinases and then form homo- or hetero-
dimers that translocate to the cell nucleus, where they act as transcription activators. STAT3 is 
activated through phosphorylation of tyrosine 705, in response to various cytokines and growth 
factors including interferons, epidermal growth factor and interleukin-6 (IL-6). The binding of IL-6 
family cytokines to gp130 receptor triggers STAT3 phosphorylation by JAK2. Hyperactivation of 
STAT3 is frequently observed in a variety of human cancers, including head and neck cancer (Yu et 
al., 2004; Yu et al, 2009; Song et al., 2000). Continuous STAT3 activation allows the growth and 
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survival of cancer cells through modulation of cell cycle regulators (e.g., cyclin D1/D2 and c-Myc), 
upregulation of anti-apoptotic proteins (e.g., Mcl- 1, Bcl-xl, and survivin). Downregulation of the 
tumor suppressor p53, and induction of angiogenesis by vascular endothelial growth factor (VEGF); 
these mechanisms lead to tumor progression and resistance to anti-cancer drugs (Frank, 2013; Yu 
et al., 2004; Yu et al, 2009).  
It has been reported that PDIA3 modulates STAT3 activity (Eufemi et al., 2004; Chichiarelli 
et al., 2010), although there are controversial results (Coe et al., 2010). For instance, PDIA3 has been 
reported to interact with STAT3 and enhance its activity in melanoma and hepatoma cells (Eufemi 
et al., 2004; Chichiarelli et al., 2010), whereas other research suggested that this PDIA3-STAT3 
complex negatively affects STAT3 DNA-binding activity (Coe et al., 2010). Hence, the role of PDIA3 
in the STAT3 activity regulation is not completely defined yet. 
As a further proof of PDIA3 presence in the cytosol, it was found in association with mTOR 
(Ramírez-Rangel et al., 2011). mTOR is a serine- threonine protein kinase, found in two multiprotein 
complexes called mTORC1 and mTORC2, which regulate cell proliferation. PDIA3 contributes to the 
assembly of mTORC1, activates the kinase activity of mTOR, and participates in the mechanism by 
which mTORC1 detects its upstream signals, such as stimulation by insulin or nutrients. PDIA3 over- 
expression induces cellular proliferation, while PDIA3 knockdown opposes the proliferation induced 
by insulin and nutrients. It is reasonable that part of this behavior is related to the mTOR-PDIA3 
interaction, considering that mTOR is involved in the regulation of proliferation (Ramírez-Rangel et 
al., 2011).  
 
1.2.4. PDIA3 localization in the nucleus  
PDIA3 was found for the first time in the nuclei of 3T3 cells and rat spermatids (Ohtani et al., 
1993) and of chicken hepatocytes, where PDIA3 was found mainly in the internal nuclear matrix 
fraction (Altieri et al., 1993). This observation was not easily accepted initially, because it was 
considered unlikely that a protein provided with an ER retention signal can escape from the 
endoplasmic reticulum. However, nowadays there is strong experimental evidence, provided by 
different laboratories with a variety of experimental techniques, that PDIA3 can be found in the 
nucleus. It has been shown that PDIA3 is present in the nuclei of HeLa cells and that it interacts 
directly with DNA (Coppari et al., 2002). PDIA3 interacts preferentially with A/T rich regions, and in 
general with DNA regions typical of the MARs (nuclear matrix associated regions) (Coppari et al., 
2002; Ferraro et al., 1999). The DNA fragments immunoprecipitated with an anti-PDIA3 antibody 
from HeLa and Raji cells were enriched in sequences contained either in introns or in 5’-flanking 
 
 
7 
regions of known genes (Chichiarelli et al., 2007; Chichiarelli et al., 2010). This can be compatible with 
a gene expression regulatory function. Furthermore, the consensus sequences for STAT3 were 
found to be associated both with this transcription factor and with PDIA3 (Chichiarelli et al., 2010). 
Because of the relatively low affinity for DNA and its lack of stringent sequence specificity, PDIA3 
cannot itself be considered as a transcription factor, but it might be considered an accessory protein 
for transcription regulation, possibly maintaining the transcription factors in their proper redox state.  
Moreover, PDIA3 shows in vitro DNA-binding properties that are strongly dependent on the 
redox state of the protein. The DNA binds to the a' domain (Grillo et al., 2002) and the binding 
requires the oxidized form of PDIA3 (Ferraro et al., 1999; Grillo et al, 2007). Evidences, from M14 
melanoma cells and HepG2 hepatoma cells, demonstrated the association of STAT3 and PDIA3 also 
in the nucleus at the level of DNA interaction (Eufemi et al., 2004; Chichiarelli et al., 2010). The PDIA3 
silencing in M14 cells causes a decrease in the expression of the STAT3-dependent gene CRP 
(Chichiarelli et al., 2010), suggesting the possibility of a positive involvement of PDIA3 in the 
signalling and/or DNA binding of STAT3.  
In NB4 leukemia cells, PDIA3 and NFkB translocate to the nucleus after treatment with 
calcitriol and phorbol ester (Wu et al., 2010), hypothesizing, again, a role of PDIA3 in the control of 
gene expression through regulation of the conformation of associated transcription factors.  
Finally, PDIA3 displays in vitro and in vivo affinity for Ref-1, a protein involved in DNA repair 
as well as in the reduction and activation of transcription factors. These two proteins appear to 
cooperate in the activation of a variety of transcription factors, which need to be in their reduced 
form in oder to bind DNA (Grillo et al.,2006).  
 
1.2.5. PDIA3 localization on cell membrane  
The first time in which it was observed that PDIA3 could escape from the ER was when 
Hirano and colleagues noticed that the protein was being secreted from 3T3 cells (Hirano et al., 
1995). Afterwards several studies showed that PDIA3 could be found on the cell surface or in 
complexes with cell membrane proteins. 
PDIA3 has been found on the surface of the sperm head, where it is required for sperm-egg 
fusion (Ellerman et al., 2006). Possibly the PDIA3 role is related to the thiol-disulfide exchange 
reactions necessary for the gamete fusion process. 
 
 
8 
One of the functions of PDIA3 on the cell surface is the binding of the hydroxylated, 
hormonal form of vitamin D3, i.e., 1α,25- dihydroxycholecalciferol (1α,25-(OH)2D3, calcitriol) 
(Nemere et al., 2004), followed by activation of non-genomic responses and the internalization and 
nuclear import of PDIA3 itself. 
It has been demonstrated that PDIA3 exists in caveolae, where it interacts with 
phospholipase A2 (PLA2) activating protein (PLAA) and caveolin-1 to initiate a rapid signaling in 
musculoskeletal cells via PLA2, phospholipase C (PLC), protein kinase C (PKC) and the ERK1/2 
family of mitogen activated protein kinases (MAPK) (Boyan et al., 2012). 
Moreover, it was recently reported that PDIA3 is associated and co-localizes with β-DG 
(one of the two subunit of the extracellular receptor dystroglycan, DG) at the plasma membrane of 
293-Ebna cells. It has been argued that PDIA3 may assist DG during its post-translational 
maturation or that it could modulate DG redox state (Sciandra et al., 2012). 
PDIA3 is also present on the platelet surface and it has been showed that its inhibition 
blocks platelet activation (Holbrook et al., 2012; Wu et al., 2012). PDIA3 is secreted by platelets and 
endothelial cells upon vascular injury and accumulates in the thrombus, where it regulates the 
activation and recruitment of other platelets (Holbrook et al., 2012).  
Dihazi and colleagues (Dihazi et al., 2011) showed that PDIA3 was found to be secreted by 
renal cells in high amounts upon profibrotic cytokine treatment, and to interact with extracellular 
matrix (ECM) proteins, such as fibronectin and collagen. These data suggest that secreted PDIA3 
could participate in ECM synthesis and stabilization, thus potentially leading to a progressive renal 
fibrosis.  
 
1.2.6. PDIA3 and diseases  
PDIA3 has been associated with several human diseases such as cancer, prion 
disorders, Alzheimer’s disease, Parkinson’s disease and hepatitis (Hetz et al., 2005; Martin 
et al., 1993; Muhlenkamp and Gill, 1998; Seliger et al., 2001; Erickson et al., 2005; Tourkova 
et al., 2005). PDIA3 expression is increased in transformed cells, and it is thought that its 
role in oncogenic transformation is directly due to its ability to control intracellular and 
extracellular redox activities (Hirano et al., 1995). An increase in PDIA3 expression has also 
been observed in the early stages of prion disease, suggesting that it may play a 
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neuroprotective role in the cellular response to prion infection (Hetz et al., 2005). 
Parkinson’s disease is characterized by the progressive loss of dopaminergic neurons of the 
substantia nigra. It has been shown that the treatment of cell lines with 6-hydroxidopamine 
(6-OHDA, a Parkinson mimetic neurotoxin that selectively kills dopaminergic neurons) 
induces PDIA3 oxidation and PDIA3-DNA conjugates formation. It was suggested that 
PDIA3 plays an early adaptive response in toxin-mediated stress (Kim-Han et al., 2007).  
 
1.2.7. PDIA3 and platelet aggregation  
Platelets play a central role in the hemostatic process, including recognizing the site of 
injury, recruiting additional platelets by intercellular signaling, adhering to each other, and interacting 
with the coagulation cascade to form a haemostatic plug. Inappropriate platelet activation, and 
subsequent thrombus formation, is important in the clinical complications of arterial atherosclerosis 
and thrombosis. Platelets are activated by a variety of agents which act to recruit additional 
platelets to the site of injury, leading to the consolidation of the aggregate.  
This activation process is initiated by the engagement of a range of specific cell surface 
receptors and associated to intracellular signaling pathways:  
Exocytosis of granular products: ADP, serotonin, calcium and fibrinogen are important in the 
recruitment of platelets to the site of injury.  
• Expression of granular membrane proteins: Adhesive proteins (e.g., GPIb, P-selectin, 
CD63, and several integrins) have been shown to be present on the membranes of 
intracellular granules and are expressed on the surface of activated platelets.  
• Eicosanoid formation: The arachidonic acid cascade is initiated, leading to 
Thromboxane A2 (TXA2) synthesis. TXA2 is a platelet agonist that plays a pro-
aggregatory role.  
• Surface expression of adhesive receptors: There is a conformational change in the αIIbβ3 integrin on the platelet surface from an inactive to an active configuration, 
exposing a fibrinogen and von Willebrand.  
Factor binding domain on the αIIbβ3 integrin that facilitates inter-platelet binding (McNicol 
and Israels, Critical Review, 2003). PDIA3 is also present on the platelet surface and it is secreted by 
endothelial cells upon vascular injury and accumulates in the thrombus, where it regulates the 
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activation and recruitment of other platelets (Holbrook et al., 2012). In fact, it has been demonstrated 
through proteomic approach that PDIA3 is upregulated and released after GPVI activation, a 
glycoprotein receptor for collagen (Holbrook et al., 2012; Zhou et al., 2014). Anti-PDIA3 antibody 
inhibits platelet aggregation, ATP secretion, calcium mobilization and activation of glycoprotein 
IIb/IIIa or fibrinogen receptor (αIIbβ3) in platelets stimulated with collagen-related peptide (CRP-
XL), while platelet factor 4 (PF4) and P-selectin expression is minimally altered (Wang et al., 2013; 
Holbrook et al., 2012). Genetically engineered mice lacking platelet- derived PDIA3 have prolonged 
tail bleeding times. PDIA3-null platelets reveal decreased platelet aggregation and decreased 
activation of αIIbβ3 (Wu et al., 2012). β3 integrins pair with αIIb on the surface of platelets to create 
fibrinogen receptor αIIbβ3, the integrin activation is accompanied by several conformational 
changes that require a new pattern of disulfide bond formation (Zhou et al., 2014). PDIA3 binding β3 
integrin in thrombin- activated platelets is probably involved in platelets aggregation, due to its 
redox activity; however, the underlying mechanism is not completely understood. (Schulman et al., 
2016).  
 
1.3. PDIA 1 protein 
Protein disulfide isomerase A1 (PDIA1) is an endoplasmic reticulum (ER)-localized thiol-
disulfide oxidoreductase that is an important folding catalyst for secretory 
pathway proteins. PDIA1 contains two active-site domains (a and a′), each containing a Cys-Gly-
His-Cys (CGHC) active-site motif. The two active-site domains share 37% sequence identity and 
function independently to perform disulfide-bond reduction, oxidation, and isomerization. 
Numerous inhibitors for PDIA1 have been reported, yet the selectivity of these inhibitors toward the 
a and a′ sites is poorly characterized (Cole et al., 2018). 
PDIA1 was the first PDI family member to be discovered. (Xu et al, 2014; Hatahet  and 
Ruddock, 2009; Goldberger et al, 1963, Venetianer and Straub, 1963) and it is a 57 kDa 
oxidoreductase and molecular chaperone that is located in the lumen of the ER and accounts for 
roughly 0.8% of the total cellular protein (Freedman, 1984). PDIA1 catalyzes the oxidation, 
reduction, and isomerization of disulfide bonds between cysteine residues on its protein substrates 
and is organized into four globular domains, a, b, b′, and a′, as well as a highly acidic C-terminal 
extension with a KDEL ER retention sequence (Xu et al, 2014; Hatahet  and Ruddock, 2009). The a 
and a′ domains functionally resemble thioredoxin and contain redox catalytic Cys-Gly-His-Cys 
(CGHC) active-site motifs. It is known that the a and a′ domains operate independently of each other 
because mutation of either active- site cysteine eliminated 50% of the catalytic activity of PDIA1 in 
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vitro, while mutations in both active sites completely abolished activity (Vuori et al, 1992). The 
noncatalytic domains, b and b′, have primary functions of spacing and substrate recruitment. The b′ 
domain is the major substrate binding site of PDIA1, containing a large hydrophobic cavity between 
helices α1 and α3 to interact with unfolded protein substrates (Kozlov et al, 2010; Klappa et al 1998). 
The dysregulation of PDIA1 activity has been implicated in a variety of diseases, including 
cancer (Xu et al, 2014 The Cancer Genome Atlas Research Network, 2008; Shai et al, 2003; Van et 
al 2009) cardiovascular diseases(Shibata et al,2001; Severino et al,2007; Laurindo et al, 2008), and 
neurodegenerative diseases (Uehara et al, 2006; Unterberger et al, 2006; Hoozemans et al, 2007; 
Hoffstrom et al 2010). PDIA1 is retained in the ER through a C-terminal KDEL retention signal 
sequence; however, the presence of PDIA1 in the extracellular milieu is well-documented (Xu et al, 
2014; Khan et al, 2011; Jiang et al 1999). Extracellular PDIA1 is involved in many biological processes 
such as platelet activation, thrombus formation, and viral infection (Khan et al, 2011).  
For example, PDIA1 can catalyze the reduction of structural disulfides on gp120, which 
results in a major conformational change, allowing the human immunodeficiency virus (HIV) to 
interact with the cell surface (Khan et al, 2011). 
The demonstrated role of increased PDIA1 activity in various diseases has spurred the 
development of a variety of small- molecule inhibitors targeting PDIA1. For example, Juniferdin, 
which was discovered in a high-throughput screen of natural products, inhibits extracellular PDIA1-
mediated disulfide-bond reduction of gp120 and inhibits the entry of HIV into host cells (Khan et al, 
2011) Quercetin 3- rutinoside binds to the b′x region of extracellular PDIA1 to induce a compact 
conformation and inhibit thrombus formation (Lin et al, 2015). T8, along with derivative JP04-042, 
sensitizes cancer cells to subtoxic concentrations of etoposide through inhibition of PDIA1 by 
reversible binding (Eirich et al, 2014). Another reversible inhibitor of PDIA1, LOC14, was identified 
from a high- throughput screen of  approximately 10000 compounds and induces an oxidized 
conformation that is neuroprotective in PC12 cells expressing mutant huntingtin protein (Kaplan et 
al 2015) 
 
1.4. Polyphenols  
Flavonoids are a large class of polyphenolic compounds ubiquitous in plants and mostly 
present in fruits, vegetables and plant-based beverages such as tea and wine (Perez-Jimenez et al., 
 
 
12 
2010). Flavonoids are further sub-classified in to flavones, flavonols, iosflavones, flavanones, 
flavanols and anthocyanidins (Manach et al., 2004; Bravo 1998).  
These physiologically active compounds have multiple well-known health beneficial 
effects. Many studies have suggested an association between consumption of flavonoids-rich food 
or beverages and the prevention of many degenerative diseases, including cancer, 
neurodegeneration and coronary heart disease and stroke (Woo et al., 2013; Hui et al., 2013; Hertog 
et al., 1993). The protection offered by flavonoids is believed to be due to their antioxidant activity. 
The aromatic rings of the flavonoid molecule allow donation and acceptance of electrons from free 
radical species (Halliwell 2006). In addition, many polyphenols regenerate the traditional 
antioxidant vitamins, vitamin C and vitamin E (Mandel et al., 2008) and act as metal chelators 
(Moridani et al., 2003). It has been suggested that, in lower amounts, flavonoids as well as 
polyphenols may exert pharmacological activity within the cells, having the potential to modulate 
intracellular signaling pathways. Many polyphenols can induce antioxidant enzymes such as 
gluthathione peroxidase, catalase, superoxide dismutase, and inhibit the expression of enzymes 
such as xanthine oxidase, which is involved in the generation of free radicals (Alvarez-Suarez et al., 
2011; Moskaug et al., 2005). However, for many of them the molecular and cellular bases of these 
activities are not known yet.  
Besides, data from literature indicate that several phytochemicals can be found in 
pomegranate fruits and can be a valuable aid in counteracting oxidative stress and preventing some 
major diseases. Pomegranate extracts have important biological properties, including anti-
atherosclerotic, antioxidant, anti-inflammatory and antigenotoxics, properties that can help in 
preventing the development of chronic and debilitating diseases such as cardiovascular illnesses, 
type 2 diabetes and cancer (Jurenka 2008; Adams et al., 2006). These activities have been 
attributed to the high content of phenolic compounds (Turrini et al., 2015; Medjakovic et al., 2013). 
The nutraceutical properties of pomegranate are not limited to the edible part of the fruit; in fact, 
non-edible fractions of fruit and tree (e.g., peel, flower, ...) contain even higher amounts of biologically 
active components. The peel of the pomegranate is rich in ellagitannins, such punicalagin, punicalin, 
gallagic acid, ellagic acid and glycosides (Fig. 6) (Akhtar et al., 2015; Masci et al., 2016). Furthermore, 
another important polyphenol that can be found in milk thistle is silibinin.   
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Figure 4. Chemical structure of punicalagin (A) silibinin (B) 
Punicalagin, a unique pomegranate compound of high molecular weight soluble in water, is 
the predominant ellagitannin. Punicalagin features important biological activities, including anti-
inflammatory, hepatoprotective and anti-genotoxic activities. However, there are currently few 
studies on punicalagin biological efficacy  (Seeram et al., 2006). 
Silibinin or silybin, the active component of silymarin, isolated from seed fruits of milk thistle 
(Silybum marianum) is a natural polyphenolic flavonoid (Sibai et al., 2005) Silibinin exhibits potent 
antioxidant, immunomodulatory, antifibrotic, antiproliferative, and antiviral activities, although the 
mechanism of action is incompletely understood (Gazak et al, 2007; Cheung et al 2010; Polyak et al, 
2013). The medicinal benefits of this plant were first reported by Theoprastus of Eresos (fourth 
century B.C.), Pedanios Dioscorides (50 A.D.), and Plinius the Elder (first century A.D.) (Flora et al, 
1998). There are more than 12,000 papers published on silibinin related substances, used as 
antioxidants, chemopreventives, anticancer agents, and especially as hepatoprotectants in the last 
10 years (Carvalho and Festi, 2011). 
 
1.5. The aim of the thesis 
The aim of this work is to make a comparative study between PDIA1 and PDIA3, the two 
main cellular disulfide isomerases, and to characterize their interaction with two polyphenols. The 
two selected polyphenols, silibinin and punicalagin, present in pomegranate and milk thistle, are 
easily accessible and their beneficial properties on human health are well known. Furthermore, 
punicalagin and silibinin have been chosen because previous studies have shown their ability to bind 
B 
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PDIA3, and punicalagin has been shown to be an excellent inhibitor of PDIA3 reductase activity 
itself. In this study the interaction of the two molecules with the two proteins was compared to 
highlight a possible selective activity and to evaluate how the analyzed substances are able to 
modify the activity and the structure of the two proteins. 
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2. Materials and methods  
2.1. Identification of specific natural PDIA3 interactors able to bind and modulate its 
activity  
2.1.1. Chemicals  
Punicalagin, silibiline, phosphate buffered saline (PBS), tris(2- carboxyethyl) phosphine 
(TCEP), dimethyl sulfoxide (DMSO), 4-(2- hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 
dithiothreitol (DTT), oxidized glutathione (GSSG), eosin isothiocyanate, glutamine, sodium pyruvate, 
fetal bovine serum (FBS), penicillin and streptomycin were purchased from Sigma-Aldrich. EDTA 
(ethylenediaminetetraacetic acid) 0.5 M solution pH 8.0 was from IBI Scientific and sodium 3 ́- (1- 
(phenylaminocarbonyl)- 3,4- tetrazolium)-bis (4-methoxy- 6-nitro) benzene sulfonic acid hydrate 
(XTT) from Biotium. SYPRO Orange was from Invitrogen.  
 
2.1.2. Protein expression and purification  
Human recombinant PDIA3 was cloned and expressed in Escherichia coli strain BL21 using 
the expression vector pET21 (Novagen) as previously described (Coppari et al., 2002). The coding 
sequence for the second redox-active domain (a’ domain, residues 377-505) was amplified by PCR 
as previously described and cloned in the expression vector pET29 (Novagen) (Grillo et al., 2007). 
Recombinant proteins were expressed in E. coli strain BL21 and purified by ammonium sulphate 
fractionation, ion exchange and heparin chromatography (Grillo et al., 2007; Grillo et al., 2006). 
Protein purification was evaluated by SDS-PAGE and concentration was determined 
spectrophotometrically (PDIA3 Ɛ280 reduced form = 44,997 M-1cm-1). 
Human recombinant PDIA1 was obtained from Lloyd W. Ruddock laboratories’ and 
expressed in E. coli strain BL21 using the expression vector pET21 (Novagen). The coding sequence 
of the protein was fused at the N terminal with an HisTaq. Recombinant proteins were expressed in 
E. coli strain BL21 and purified by niqel chromatography, followed by ions exchange cromatography. 
Protein purification was evaluated by SDS-PAGE and concentration was determined 
spectrophotometrically. (PDIA1 Ɛ280 reduced form = 44,567 M-1cm-1). 
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2.1.3. Fluorescence Quenching Measurements  
The PDIA3/PDIA1 interactions with punicalagin and silibilin were evaluated by fluorimetric 
titration. Fluorescence spectra were recorded using a SPEX- FluoroMax spectrofluorimeter (Horiba 
Scientific) from 300 to 400 nm with excitation at 290 nm using a 10 mm path length quartz cuvette 
and under continuous stirring. The excitation and emission slits were both set to 2 nm and scan 
speed was 120 nm·min-1.  
First, PDIA3 was reduced adding 1 mM DTT to 65 μM PDIA3 working solution. Then, aliquots 
of freshly reduced PDIA3 (0.2. μM final concentration) was diluted in PBS containing EDTA 0.2 mM 
final concentration and DTT 0.1 mM final concentration, and titrated in quartz cuvette by stepwise 
additions (addition of 4µL for 5 times), at 5 min time intervals, of silibiline solution (1 mM in 
PBS/DMSO 40:1 freshly prepared from a 40mM stock solution in DMSO) or of punicalagin solution 
(1mM in PBS freshly prepared from a 5 mM stock solution in water). PDIA1 was reduced adding 1 mM 
DTT to 75 μM working solution. Then, aliquots of freshly reduced PDIA1 (0.2 μM final concentration) 
was diluted in PBS containing EDTA 0.2 mM final concentration and DTT 0.1 mM final concentration, 
the following procedure was the same. 
Silibiline and punicalagin can both absorb light at the excitation and emission wavelengths. 
To minimize the inner-filter effect, we limited the highest concentration reached in the titration test 
up to 10 μM. All experiments were carried out at 25°C. The blank spectra (punicalagin or silibiline 
without protein) were recorded under the same experimental conditions and subtracted from the 
corresponding polyphenol-protein system to correct the fluorescence background. Fluorescence 
intensities recorded at 338 nm were used for quenching analysis and obtained data, as the average 
of at least three independent titration experiments.  
 
2.1.4. Isothermal titration calorimetry (ITC)  
The thermodynamic analysis of PDIA3/PDIA1- punicalagin/silibinin interactions were 
obtained using the MicroCal ITC (Malvern Instruments Ltd.). PDIAs were extensively dialyzed and 
poliphenols were dissolved in the same buffer. The sample cell (0.2 ml) was filled with PDIA3 (25 
μM) and the syringe with punicalagin or silibinin (250 μM solution). Ligand solution was then injected 
into the cell in 19 aliquots of 2 μL for 4 s (the first injection was 0.4 μL for 0.8 s) with delay intervals 
between injections of 200 s. Syringe stirring speed was set to 750 rpm. PDIAs-poliphenols 
interactions were analyzed in both non-reducing and reducing conditions. In the end, 1 mM DTT was 
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added to protein and ligand solutions to ensure protein reduction. To correct the heat of dilution, 
titration of punicalagin and silibinin into a buffer without PDIAs were carried out. The 
thermodynamic data were processed with Origin 7.0 software provided by MicroCal and used to 
calculate molar enthalpy, affinity constant and the stoichiometry of the reactions. 
 
2.1.5. Statistical analysis  
Fluorescence quenching constant (KSV) values were given as means ± standard deviation 
and values of disulfide reductase activity were expressed in percentage of control sample ± relative 
standard deviation. All measurements were repeated at least three times. Dunnett’s test was used 
to compare the obtained reductase activity data with the activity of the untreated protein and a p-
value of < 0.01 was considered as statistically significant. Statistical comparisons were performed 
using ONE-WAY or TWO-WAY Analysis of Variance (ANOVA) and post hoc Bonferroni’s test, with 
different poliphenols treatments as variables, using GraphPad Prism 5.0. The means of the data are 
presented with SEM. Statistical significance threshold was set to p < 0.05.  
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3. Results and Discussion 
3.1 Protein extraction and purification 
To proceed with the comparative analysis between the two proteins it was necessary to 
obtain them in recombinant form through expression in bacteria and subsequent purification by 
chromatographic techniques. 
3.1.1. PDIA3 
The supernatant, containing PDIA3 and obtained from the centrifuge performed after 
dialysis, is passed into a Macro-Prep anion exchange column Q (Biorad); after washing with Tris-
HCl buffer 20 mM pH 8.0, NaCl 20 mM, the column is eluted first using a solution at the concentration 
of 150 mM NaCl in Tris-HCl 20 mM, pH 8.0 and then increasing the concentration of NaCl up to 1M 
(Figure 7). We have collected the non-related and the obtained eluate at the two salt concentrations 
in two different eppendorfs for the electrophoretic run, the result of which is visible in the image 
below. In the gel in figure 5 we see (from left to right): the marker, which indicates the molecular 
weight of our protein; the pellet derived from the last centrifugation before precipitation with 
ammonium sulphate; the supernatant derived from the last centrifugation before the addition of 
ammonium sulphate; the centrifuge pellet derived after 30% ammonium sulfate precipitation; the 
pellet derived from the centrifuge carried out after the precipitation with 75% ammonium sulphate 
where our protein is present; the pellet derived from the centrifuge performed after dialysis; the 
supernatant of the same centrifuge; the non-related; the eluate at 150 mM of the first anionic 
exchange chromatography; the 1 M eluate of the same chromatography. 
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Figure 5. Chromatogram of the Macro-Prep anion exchange column Q 
As we see, the protein is present in the supernatant to which 30% ammonium sulfate will 
be added, in the pellet obtained after precipitation with 75% ammonium sulphate; in the supernatant 
to be dialyzed and naturally in the eluate at 150 mM of the anion exchange chromatography. The 
other samples act as a negative control. 
 
Figure 6. SDS-PAGE of the fractions obtained during sonication, precipitation in ammonium 
sulphate and eluted from the column 
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The 150 mM saline eluate is passed into a chromatographic column containing heparin 
(Figure 7). The column is eluted using a linear gradient from 20 to 1M of NaCl in Tris-HCl 20 mM, pH 
8.0 (elution for 60 minutes, flow 1 ml / min). 
Figure 7. Chromatogram of the column containing heparin. 
The eluted fractions are analyzed by SDS-PAGE to see which contain the greatest amount 
of PDIA3 (Figure 8). 
 
Figure 8. SDS-PAGE of the fractions eluted from the column containing heparin 
The selected fractions are combined and dialysed in Tris HCl 20mM pH 8.0 NaCl 20mM 
buffer overnight. After dialysis, the solution is again passed on a Macro-Prep Q anion exchange 
column (Figure 9). The elution is carried out in an increasing gradient of NaCl in Tris-HCl pH 8.0 from 
0 to 250 mM (elution for 35 minutes, flow 1 ml / min). 
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Figure 9. Chromatogram of the Macro-Prep anion exchange column Q 
 
Again, with an SDS-PAGE the samples with the highest amount of protein are highlighted 
(Figure 10). 
Figure 10. SDS-PAGE of the fractions eluted from the Macro-Prep column Q 
 
Samples with greater amounts of protein are combined and used to determine the latter's 
concentration by spectrophotometry, using the estimated molar extinction coefficient (ε 280nm / 
1M = 44947.5). 
 
 
22 
3.1.2 PDIA 1 
After the dialysis the solution is centrifuged and the supernatant is passed into a column 
containing nickel, to which the histidine tag of our protein will bind; the column is eluted using a 
gradient from 0 to 150 mM in 30 minutes of a solution containing 20 mM Tris-HCl, 100 mM NaCl and 
1 M imidazole pH 8 (figure 11). 
Figure 11. Chromatogram of the column containing nickel 
The eluted fractions are analyzed by SDS-PAGE to see which of these contain the greatest 
amount of protein. In Figure 12 we see (from left to right): a) the supernatant derived from the last 
centrifugation before the addition of ammonium sulphate; b) the pellet derived from the last 
centrifugation before precipitation with ammonium sulphate; c) the centrifuge pellet derived after 
30% ammonium sulfate precipitation; d) the pellet derived from the centrifuge carried out after the 
precipitation with 75% ammonium sulphate (where our protein is present); e) the supernatant 
derived from the centrifuge performed after dialysis; f) the pellet of the same centrifuge; the non-
related; the eluate of nickel chromatography; the PDIA1; the marker. 
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Figure 12. SDS-PAGE of the fractions obtained during sonication, precipitation in ammonium 
sulphate and eluted from the nickel column. 
As we can see from the figure 12, PDIA1 (present in the eluate of nickel chromatography) is 
much less clean compared to PDIA3 which, not having a tag, was purified using the series of 
chromatographies described above. To eliminate the residual contaminants, the eluate of the nickel 
chromatography is dialysed in Tris HCl 20mM pH 8.0 NaCl 20mM buffer overnight and then passed 
on a Macro-Prep Q anion exchange column (Figure 13). The elution is carried out in a growing 
gradient of NaCl in Tris-HCl pH 8. 0 from 0 to 25% (elution for 35 minutes, flow 1 ml / min). 
Figure 13. Chromatogram of the Macro-Prep anion exchange column Q 
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With an SDS-PAGE (Figure 14) the samples with the highest quantity of protein are 
highlighted and these are joined and used to determine the concentration of the latter by 
spectrophotometry, using the estimated molar extinction coefficient (ε 280nm / 1M = 44947, 5). 
Figure 14. SDS-PAGE of the fractions eluted from the Macro-Prep column Q 
3.2 Fluorescence Quenching Analysis 
The first comparative study between the two proteins, PDIA1 and PDIA3, was 
performed by quenching analysis of the intrinsic fluorescence of  each protein. Both proteins 
possess an intrinsic fluorescence due to the presence of tryptophan residues. PDIA3 
contains 3 tryptophan residues, 2 of which are located near the active redox sites, W56 and 
W405 and a third on the domain b ’and partially exposed (Figure 15). 
 
Figure 15. Three-dimensional structure of PDIA3 with the three tryptophan residues 
highlighted 
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PDIA1 instead contains 5 tryptophan residues W52, W128 present on domain a, W364, 
W396, W407 on domain a ’. While the residues W52 and W396 located near the redox sites are 
totally exposed, the residues W128 and W407 are internal and the residue W364 is partially 
exposed (Figure 16). 
Figure 16. Three-dimensional structure of PDIA1 with the 5 residues of tryptophan 
highlighted 
The protein concentrations and the protein / ligand ratios used for all the experiments are 
the result of a compromise between the absorption of the ligands used and of the protein with 
respect to the recorded fluorescence intensity. The reason for this is to avoid the problems 
connected with the inner-filter effect, namely the absorption of light mainly by the polyphenols used 
at the excitation or emission wavelengths used for fluorescence analysis, equal respectively to 290 
nm for excitation and 338 nm for emission. Absorption at these wavelengths could lead to a 
reduction in the fluorescence emission not due to direct quenching (i.e. interaction between ligand 
and protein). 
Since the polyphenols used have a significant absorption in the frequency range 
corresponding to the wavelengths used for the excitation and emission of the fluorophore it was 
necessary to minimize their final concentration. Correspondingly, the protein concentration has also 
been reduced to maintain an adequate protein-ligand ratio. For this reason, after an initial screening 
at protein concentrations of 0.1 µM, 0.2 µM and 0.5 µM all the experiments were then conducted at 
the intermediate concentration maintaining a protein / ligand ratio not exceeding 1:20, or a final 
ligand concentration of 4µM. 
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At each addition of ligand aliquots the emission spectrum of the protein from 300nm to 
400nm was recorded three times and the average reading value at each wavelength was then used 
in subsequent quenching analyzes. Each protein was analyzed both in a completely reduced form 
and in a non-reduced form. Figures 17 and 18 show the fluorescence emission spectra of the two 
PDIAs in the presence of increasing ligand concentrations and analyzed under completely reduced 
conditions (figures 17A and 17B) and not reduced (figures 20A and 20B). 
 
Figure 17.  Emission spectrum of the fluorescence of PDIA1 (A) and PDIA3 (B) in the reduced forms 
at increasing concentrations of punicalagin (left) and silibinin (right). The protein concentration is 
0.2μM and the final protein ligand ratio is 1:20. 
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Figure 18.  Emission spectrum of the fluorescence of PDIA1 (A) and PDIA3 (B) in the non-reduced 
forms at increasing concentrations of punicalagin (left) and silibinin (right). The protein 
concentration is 0.2μM and the final protein ligand ratio is 1:20. 
To obtain the Stern-Volmer constant (Ksv) for each interaction the fluorescence emission 
value at 338nm of the protein (F0) was compared with the fluorescence value always at 338nm in 
the presence of increasing concentrations of ligand (F) and the values obtained were graphically 
analyzed using the following equation: (Fo/F = 1 + KSV[L]),  (figures 19A and 19B). 
Based on the results obtained, it can be observed that both silibinin and punicalagin are able 
to generate a quenching effect with Stern-Volmer constants always greater than 104 M-1. 
Considering that the Stern-Volmer constant is equal to the quenching constant for the average life 
time of the fluorophore (KSV=Kqτ) and that for the residue of tryptophan tau is in the order of 10⁻⁸ 
sec, the calculable values of Kq they are always greater than 2x1010 suggesting that an interaction 
is established between the analyzed polyphenols and the two PDIAs. 
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Figure 19. Analysis of fluorescence quenching data of PDIA1 and PDIA3 proteins in 
reduced form (A) and not reduced (B) in the presence of increasing concentrations of punicalagin 
(left) and silibinin (right). 
By analyzing the fluorescence spectra of the two proteins in the presence of silibinin and 
punicalagin, a red shift in the maximum emission can also be seen, suggesting that the 
microenvironment around the tryptophan residue becomes more polar (figures 17 and 18). The 
values of KSV constants, which may be correlated with affinity, obtained by the interaction of the 
two proteins in reduced and non-reduced forms with punicalagin and silibinin, are shown in Figure 
20.. 
Punicalagin and silibinin have opposite affinity profiles towards the two PDIAs. In fact, 
punicalagin has a greater affinity for PDIA3 both in the reduced form and in the non-reduced form, 
while the silibinin shows a better affinity for PDIA1 (Figure 20). The values of the dissociation 
constants Kd and the number of interaction sites n together with the Kq values were calculated and 
reported in Table 1. 
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Figure 20. Comparison between the KSV values obtained for PDIA1 and PDIA3 proteins in reduced 
(left) and non-reduced (right) form in the presence of increasing concentrations of punicalagin and 
silibinin. The data were analyzed by t-test and the statistically significant differences are indicated 
with asterisks. 
 
Table 1: Parameters related to the interaction between PDIA1 and PDIA3, in reduced and non-
reduced form, with punicalagin and silibinin. The protein concentration is 0.2μM and the final 
protein ligand ratio is 1:10. 
 
KSV 
(M-1) 
Kq 
(M-1s-1) 
Kd 
(M) 
n 
Reduced PDIA1 + silibinin 7.5x104 7.5x1012 18.2x10-6 0.675 
Reduced PDIA3 + silibinin 4.2x104 4.2x1012 30.1x10-6 0.812 
Reduced PDIA1 + punicalagin 9.9x104 9.9x1012 11.9x10-6 0.934 
Reduced PDIA3 + punicalagin 16.2x104 16.2x1012 5.9x10-6 1.005 
     
Non-reduced PDIA1 + silibinin 7.65x104 7.65x1012 15.8x10-6 0.764 
Non-reduced PDIA3 + silibinin 4.45x104 4.45x1012 23.1x10-6 0.972 
Non-reduced PDIA1 + punicalagin 18.6x104 18.6x1012 4.9x10-6 1.119 
Non-reduced PDIA3 + punicalagin 24.7x104 24.7x1013 4.03 x10-6 1.085 
 
As already mentioned, all the values of Kq  are higher than 1010 M-1s-1, highlighting that the 
nature of the link between silibinin and punicalagin is not dynamic but involves the formation of 
stable complexes. The Kd values are between 5µM and 30µM indicating a good affinity between the 
proteins and the polyphenols used. The values of n are always close to the unit indicating that the 
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binding site is only one, even if the tryptophan residues that are able to give quenching are greater 
than one and mainly present on the two redox domains (a and a '). 
3.3  ANALYSIS BY MEANS OF ITC CALORIMETRY  
The binding affinities between the two PDIAs and the polyphenols have been further 
studied by ITC. This technique is not affected by the absorption characteristics of the ligands used 
and also provides information on the thermodynamics and stoichiometry of the interaction between 
the two PDIAs and the analyzed polyphenols. All experiments were performed on the reduced forms 
of PDIAs. Figures 21 and 22 show the titration profiles of the two PDIAs in reduced forms in the 
presence of increasing concentrations of punicalagin and silibinin. 
 
Figure 21. Titration profile of PDIA1 protein in reduced form in the presence of increasing 
concentrations of silibinin and punicalagin at a temperature of 25 ° C. The protein concentration is 
25μM and the final protein: ligand ratio is 1: 2. 
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Figure 22. Titration profile of PDIA3 protein in reduced form in the presence of increasing 
concentrations of silibinin and punicalagin at a temperature of 25 ° C. The protein concentration is 
25μM and the final protein: ligand ratio is 1: 2 
These analysis, performed in duplicate, confirmed the formation of the protein-ligand complexes 
with Kd values which in all cases are in the order of micromolar concentration (Table 2) and which 
are lower than the values obtained from the quenching assays of the fluorescence (Table 1). 
Furthermore, there is no appreciable variation in the values of the association constants between 
the two proteins and the ligands considered, indicating a similar affinity, with the exception of the 
interaction between PDIA1 and punicalagin, characterized by a greater affinity even if with a value 
of n plus low compared to other interactions. We can explain this apparent inconsistency with the 
data obtained from the quenching analysis considering that the fluorimetric technique, unlike the 
ITC, has limits. In fact, in addition to the inner effect phenomenon, the fluorescence quenching is also 
affected by the distance of the ligand binding site from the fluorophore. The more the ligand is away 
from the tryptophan, the less quenching of the fluorescence can be observed. 
With this assumption we can motivate the ever higher values of Kd found in the quenching with 
respect to the ITC. We can also hypothesize always comparing the values of Kd obtained with the 
two techniques that the interaction with silibinin, characterized by lower quenching values, concerns 
a binding site further from the fluorophore than punicalagin in both PDIA3 and PDIA1 . However, we 
must also consider the presence of two tryptophan residues for each redox domain, but positioned 
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differently, in PDIA1 which may explain the lower degree of quenching observed for this protein. The 
thermodynamic parameters obtained from the analysis by ICT are summarized in table 2. 
Table 2: Thermodynamic parameters related to the interaction between PDIA1 and PDIA3 with 
punicalagin and silibinin at a temperature of 25 ° C. The protein concentration is 25μM and the final 
protein ligand ratio is 1: 2. 
 N 
Ka 
(M-1) 
Kd 
(M) 
ΔH 
(cal/mol) 
ΔS 
(cal/mol/deg) 
Reduced PDIA1  + silibinin 0.631 
0.596 
3.07x105 
3.80x105 
3.26x10-6 
2.63x10-6 
-11850 
-9865 
-14.7 
-7.56 
Reduced PDIA3  + silibinin 0.924 
0.773 
5.75x105 
4.48x105 
1.74x10-6 
2.23x10-6 
-1358 
-1746 
21.8 
20.0 
Reduced PDIA1 + punicalagin 0.136 
0.314 
1.07x106 
2.56x107 
0.93x10-6 
0.04x10-6 
-3263 
-1122 
16.6 
30.1 
Reduced PDIA3  + punicalagin 0.818 
0.374 
3.83x105 
4.78x105 
2.61 x10-6 
2.09x10-6 
-705.7 
-1139 
23.2 
22.2 
The interactions between punicalagin and PDIA1 and PDIA3 as well as that between silibinin 
and PDIA3 are enthalpically and entropically favored. The enthalpic negative values are due to the 
contribution of H bonds and Van der Waals forces in favoring protein-ligand interactions. The 
hydrophobic interactions and the greater degree of freedom of the solvent instead justify the 
positive entropic values. The ΔH of the PDIA1-silibinin interaction is much more negative than the 
other characterized interactions and is compensated by a strong negative entropic contribution. It 
can therefore be assumed that in addition to the Van der Waals forces and the hydrogen bonds there 
are other conditions that favor or are induced during this interaction. In fact, negative ΔS suggests 
that PDIA1, following interaction with silibinin, undergoes a conformational change that exposes a 
greater number of polar amino acid residues which structure the solvent water molecules. The result 
is a decrease in the degree of freedom of the solvent and a decrease in the entropic value associated 
with the interaction. This conformational change can be confirmed by the red fluorescence shift 
observed during the quenching analysis, which can be associated to a tryptophan exposure in a 
more polar environment and a consequent negative entropic effect on the solvent molecules 
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4. Conclusions 
The aim of the present study was to compare the binding of two polyphenols, punicalagin 
and silibinin, with the two main proteins belonging to the disulphide isomerase protein family, PDIA1 
and PDIA3. Although the two proteins share a good structural similarity and similar enzymatic 
functions, within the cell their role is differentiated with PDIA3 involved in a greater number of 
functions besides the canonical ones performed within the endoplasmic reticulum. During studies 
conducted in the laboratory, several molecules with polyphenolic structure were found to be good 
ligands of the PDIA3 isoform of the disulfide proteins isomerase and in particular, it was recently 
observed that punicalagin is a powerful inhibitor of its reductase activity. 
Given the different role played by the two disulfide isomerase proteins inside the cell, it is 
important to be able to compare both the binding and the effect on the activity and conformation of 
the two proteins by punicalagin to evaluate a possible selective effect. At the same time the analysis 
was extended to another polyphenol, silibinin, which, although not having a particular inhibitory 
activity on PDIA3, instead showed an affinity comparable to punicalagin. From the comparative 
analysis it emerged that the two polyphenols are able to bind both proteins but the interaction that 
is established produces different effects. This is certainly connectable to a different site of 
interaction of the two molecules, both between them and in relation to the two PDIs. In fact, while 
the punicalagin interacts with regions near to the site to redox activity, with consequent reduction 
of the enzymatic activity, clearly more pronounced in comparison to the PDIA3, the silibinin very 
probably interacts with a site more distant from the sites to redox activity. This can certainly be due 
to the different structure of the two ligands, planar in the case of silibinin, and with a three-
dimensional shape more complex in the case of punicalagin.  
Moreover, the two molecules show a different interaction with the two PDI, which can be 
connected with the different conformation structure of the proteins themselves. This makes 
punicalagin a promising selective inhibitor for PDIA3 and the further characterization of the 
interaction site may allow for possible changes to its chemical structure that accentuate this 
selectivity. At the same time silibilin, although not showing a particular inhibitory action, if not limited 
towards PDIA1, could be used to modulate the interaction of the PDIs themselves with other 
substrate proteins involved in the formation of macromolecular complexes responsible for the 
cellular activities of the two PDIAs . Indeed, a stabilizing effect on the conformation of PDIA1 alone 
by this polyphenol was observed. Also in this case a diversified interaction with the two PDIs would 
make silibinin a selective modulator. Further studies, extended to other polyphenolic substances, 
will allow the identification of PDI modulators / inhibitors with high specificity and selectivity. 
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Gruber, C., Čemažar, M., Heras, B., Martin, J. and Craik, D. (2006). Protein disulfide isomerase: the 
structure of oxidative folding. Trends in Biochemical Sciences, 31(8), 455- 464.  
Hashimoto, S. and Saido, T. (2018). Critical review: involvement of endoplasmic reticulum stress in 
the aetiology of Alzheimer's disease. Open Biology, 8(4), 180024.  
Hatahet, F. and Ruddock, L. (2007). Substrate recognition by the protein disulfide isomerases. FEBS 
Journal, 274(20), 5223-5234.  
Hatahet, F. and Ruddock, L. (2009). Protein Disulfide Isomerase: A Critical Evaluation of Its Function 
in Disulfide Bond Formation. Antioxidants & Redox Signaling, 11(11), 2807-2850.  
Hatahet, F., and Ruddock, L. W. (2009) Protein disulfide isomerase: a critical evaluation of its 
function in disulfide bond formation. Antioxid. Redox Signaling 11, 2807−2850.  
He, J., Shi, W., Guo, Y. and Chai, Z. (2014). ERp57 modulates mitochondrial calcium uptake through 
the MCU. FEBS Letters, 588(12), 2087-2094.  
Hettinghouse, A., Liu, R. and Liu, C. (2018). Multifunctional molecule ERp57: From cancer to 
neurodegenerative diseases. Pharmacology & Therapeutics, 181, 34-48.  
Hetz, C., Russelakis-Carneiro, M., Walchli, S., Carboni, S., Vial-Knecht, E., Maundrell, K., Castilla, J. and 
Soto, C. (2005). The Disulfide Isomerase Grp58 Is a Protective Factor against Prion Neurotoxicity. 
Journal of Neuroscience, 25(11), 2793-2802.  
Hirano, N., Shibasaki, F., Sakai, R., Tanaka, T., Nishida, J., Yazaki, Y., Takenawa, T. and Hirai, H. (1995). 
Molecular Cloning of the Human Glucose-Regulated Protein ERp57/GRP58, a Thiol-Dependent 
Reductase. Identification of its Secretory form and Inducible Expression by the Oncogenic 
Transformation. European Journal of Biochemistry, 234(1), 336-342.  
Hoffstrom, B. G., Kaplan, A., Letso, R., Schmid, R. S., Turmel, G. J., Lo, D. C., and Stockwell, B. R. (2010) 
Inhibitors of protein disulfide isomerase suppress apoptosis induced by misfolded proteins. Nat. 
Chem. Biol. 6, 900−906.  
Holbrook, L., Sasikumar, P., Stanley, R., Simmonds, A., Bicknell, A. and Gibbins, J. (2012). The platelet-
surface thiol isomerase enzyme ERp57 modulates platelet function. Journal of Thrombosis and 
Haemostasis, 10(2), 278-288.  
 
 
37 
Holmgren, A. (1985). Thioredoxin. Annu Rev Biochem, 54, 237-271.  
Hoozemans, J. J., van Haastert, E. S., Eikelenboom, P., de Vos, R. A., Rozemuller, J. M., and Scheper, W. 
(2007) Activation of the unfolded protein response in Parkinson’s disease. Biochem. Biophys. Res. 
Commun. 354, 707−711.  
Jiang, X. M., Fitzgerald, M., Grant, C. M., and Hogg, P. J. (1999) Redox control of exofacial protein 
thiols/disulfides by protein disulfide isomerase. J. Biol. Chem. 274, 2416−2423.  
K. Flora, M. Hahn, H. Rosen, K. Benner, Milk thistle (Silybum marianum) for the therapy of liver 
disease, Am. J. Gastroenterol. 93 (1998) 139e143.  
Kaplan, A., Gaschler, M. M., Dunn, D. E., Colligan, R., Brown, L. M., Palmer, A. G., 3rd, Lo, D. C., and 
Stockwell, B. R. (2015) Small molecule-induced oxidation of protein disulfide isomerase is neuro- 
protective. Proc. Natl. Acad. Sci. U. S. A. 112, E2245−2252.  
Karala, A. and Ruddock, L. (2010). Bacitracin is not a specific inhibitor of protein disulfide isomerase. 
FEBS Journal, 277(11), 2454-2462.  
Karala, A., Lappi, A. and Ruddock, L. (2010). Modulation of an Active-Site Cysteine pKa Allows PDI 
to Act as a Catalyst of both Disulfide Bond Formation and Isomerization. Journal of Molecular 
Biology, 396(4), 883-892.  
Khan, M. M., Simizu, S., Lai, N. S., Kawatani, M., Shimizu, T., and Osada, H. (2011) Discovery of a small 
molecule PDI inhibitor that inhibits reduction of HIV-1 envelope glycoprotein gp120. ACS Chem. Biol. 
6, 245−251.  
Khanal, R. and Nemere, I. (2007). The ERp57/GRp58/1,25D3-MARRS Receptor: Multiple 
Functional Roles in Diverse Cell Systems. Current Medicinal Chemistry, 14(10), 1087-1093.  
Kim-Han, J. and O'Malley, K. (2007). Cell Stress Induced by the Parkinsonian Mimetic, 6- 
Hydroxydopamine, is Concurrent with Oxidation of the Chaperone, ERp57, and Aggresome 
Formation. Antioxidants & Redox Signaling, 9(12), 2255-2264.  
Klappa, P., Ruddock, L. W., Darby, N. J., and Freedman, R. B. (1998) The b′ domain provides the 
principal peptide-binding site of protein disulfide isomerase but all domains contribute to binding of 
misfolded proteins. EMBO J. 17, 927−935.  
Klappa, P., Ruddock, L., Darby, N. and Freedman, R. (1998). The b' domain provides the principal 
peptide-binding site of protein disulfide isomerase but all domains contribute to binding of misfolded 
proteins. The EMBO Journal, 17(4), 927-935.  
Kortemme, T., Darby, N. and Creighton, T. (1996). Electrostatic Interactions in the Active Site of the 
N-T erminal Thioredoxin-like Domain of Protein Disulfide Isomerase. Biochemistry, 35(46), 14503-
14511.  
Kozlov, G., Maattanen, P., Schrag, J., Pollock, S., Cygler, M., Nagar, B., Thomas, D. and Gehring, K. 
(2006). Crystal Structure of the bb′ Domains of the Protein Disulfide Isomerase ERp57. Structure, 
14(8), 1331-1339.  
Kozlov, G., Maattanen, P., Thomas, D. Y., and Gehring, K. (2010) A structural overview of the PDI 
family of proteins. FEBS J. 277, 3924−3936.  
 
 
38 
Lappi, A., Lensink, M., Alanen, H., Salo, K., Lobell, M., Juffer, A. and Ruddock, L. (2004). A Conserved 
Arginine Plays a Role in the Catalytic Cycle of the Protein Disulphide Isomerases. Journal of 
Molecular Biology, 335(1), 283-295.  
Laurindo, F. R., Fernandes, D. C., Amanso, A. M., Lopes, L. R., and Santos, C. X. (2008) Novel role of 
protein disulfide isomerase in the regulation of NADPH oxidase activity: pathophysiological 
implications in vascular diseases. Antioxid. Redox Signaling 10, 1101− 1113.  
Lecanu, L., Rammouz, G., McCourty, A., Sidahmed, E., Greeson, J. and Papadopoulos, V. (2010). 
Caprospinol reduces amyloid deposits and improves cognitive function in a rat model of Alzheimer's 
disease. Neuroscience, 165(2), 427-435.  
Lee, A. (1981). The accumulation of three specific proteins related to glucose-regulated proteins in a 
temperature-sensitive hamster mutant cell line K12. Journal of Cellular Physiology, 106(1), 119-125.  
Li, Y. and Camacho, P. (2003). Ca2+-dependent redox modulation of SERCA 2b by ERp57. The 
Journal of Cell Biology, 164(1), 35-46.  
Lin, L., Gopal, S., Sharda, A., Passam, F., Bowley, S. R., Stopa, J., Xue, G., Yuan, C., Furie, B. C., 
Flaumenhaft, R., Huang, M., and Furie, B. (2015) Quercetin-3-rutinoside Inhibits Protein Disulfide 
Isomerase by Binding to Its b′x Domain. J. Biol. Chem. 290, 23543−23552.  
Lindquist, J., Jensen, O., Mann, M. and Hämmerling, G. (1998). ER-60, a chaperone with thiol-
dependent reductase activity involved in MHC class I assembly. The EMBO Journal, 17(8), 2186-
2195.  
Martin, J., Kenna, J., Martin, B., Thomassen, D., Reed, G. and Pohl, L. (1993). Halothane hepatitis 
patients have serum antibodies that react with protein disulfide isomerase. Hepatology, 18(4), 858-
863.  
McNicol, A. and Israels, S. (2003). Platelets and Anti-platelet Therapy.Journal of Pharmacological 
Sciences, 93(4), 381-396.  
Molinari, M. and Helenius, A. (1999). Glycoproteins form mixed disulphides with oxidoreductases 
during folding in living cells. Nature, 402(6757), 90-93.  
Morjana, N. and Gilbert, H. (1991). Effect of protein and peptide inhibitors on the activity of protein 
disulfide-isomerase. Biochemistry, 30(20), 4985-4990.  
Muhlenkamp, C. and Gill, S. (1998). A Glucose-Regulated Protein, GRP58, Is Down- Regulated in 
C57B6 Mouse Liver after Diethylhexyl Phthalate Exposure. Toxicology and Applied Pharmacology, 
148(1), 101-108.  
Nemere, I., Farach-Carson, M., Rohe, B., Sterling, T., Norman, A., Boyan, B. and Safford, S. (2004). 
Ribozyme knockdown functionally links a 1,25(OH)2D3 membrane binding protein (1,25D3-
MARRS) and phosphate uptake in intestinal cells. Proceedings of the National Academy of Sciences, 
101(19), 7392-7397.  
Nemere, I., Garbi, N., Hammerling, G. and Hintze, K. (2012). Role of the 1,25D3-MARRS receptor in 
the 1,25(OH)2D3-stimulated uptake of calcium and phosphate in intestinal cells. Steroids, 77(10), 
897-902.  
 
 
39 
Ni, M. and Lee, A. (2007). ER chaperones in mammalian development and human diseases. FEBS 
Letters, 581(19), 3641-3651.  
Nishitsuji, K., Tomiyama, T., Ishibashi, K., Ito, K., Teraoka, R., Lambert, M., Klein, W. and Mori, H. 
(2009). The E693Δ Mutation in Amyloid Precursor Protein Increases Intracellular Accumulation of 
Amyloid β Oligomers and Causes Endoplasmic Reticulum Stress-Induced Apoptosis in Cultured 
Cells. The American Journal of Pathology, 174(3), 957-969.  
Noiva, R., Freedman, R. and Lennarz, W. (1993). Peptide binding to protein disulfide isomerase 
occurs at a site distinct from the active sites. J. Biol. Chem., 268, 19210–19217.  
Noiva, R., Kimura, H., Roos, J. and Lennarz, W. (1991). Peptide binding by protein disulfide isomerase, 
a resident protein of the endoplasmic reticulum lumen. J. Biol. Chem, 266, 19645– 19649.  
Ohtani, H., Wakui, H., Ishino, T., Komatsuda, A. and Miura, A. (1993). An isoform of protein disulfide 
isomerase is expressed in the developing acrosome of spermatids during rat spermiogenesis and is 
transported into the nucleus of mature spermatids and epididymal spermatozoa. Histochemistry, 
100(6), 423-429.  
Oliver, J., Roderick, H., Llewellyn, D. and High, S. (1999). ERp57 Functions as a Subunit of Specific 
Complexes Formed with the ER Lectins Calreticulin and Calnexin. Molecular Biology of the Cell, 
10(8), 2573-2582.  
Oliver, J., van der Wal, F., Bulleid, N. and High, S. (1997). Interaction of the Thiol- Dependent 
Reductase ERp57 with Nascent Glycoproteins. Science, 275(5296), 86-88.  
Ozaki, T., Yamashita, T. and Ishiguro, S. (2008). ERp57-associated mitochondrial μ-calpain 
truncates apoptosis-inducing factor. Biochimica et Biophysica Acta (BBA) - Molecular Cell 
Research, 1783(10), 1955-1963.  
Pirneskoski, A., Ruddock, L., Klappa, P., Freedman, R., Kivirikko, K. and Koivunen, P. (2000). Domains 
b′ and a′of Protein Disulfide Isomerase Fulfill the Minimum Requirement for Function as a Subunit 
of Prolyl 4-Hydroxylase. Journal of Biological Chemistry, 276(14), 11287-11293.  
Plácido, A., Pereira, C., Duarte, A., Candeias, E., Correia, S., Santos, R., Carvalho, C., Cardoso, S., Oliveira, 
C. and Moreira, P. (2014). The role of endoplasmic reticulum in amyloid precursor protein processing 
and trafficking: Implications for Alzheimer's disease. Biochimica et Biophysica Acta (BBA) - 
Molecular Basis of Disease, 1842(9), 1444- 1453.  
Polachi, N., Bai, G., Li, T., Chu, Y., Wang, X., & Li, S. et al. (2016). Modulatory effects of silibinin in various 
cell signaling pathways against liver disorders and cancer – A comprehensive review.	European 
Journal Of Medicinal Chemistry,	123, 577-595. 
Polyak SJ, Oberlies NH, Pécheur E-I, Dahari H, Ferenci P, Pawlotsky J-M. Silymarin for HCV infection. 
Antivir Ther 2013;18(2):141–7. 
Quan, H., Fan, G. and Wang, C. (1995). Independence of the Chaperone Activity of Protein Disulfide 
Isomerase from Its Thioredoxin-like Active Site. Journal of Biological Chemistry, 270(29), 17078-
17080.  
 
 
40 
Ramirez-Rangel, I., Bracho-Valdes, I., Vazquez-Macias, A., Carretero-Ortega, J., Reyes- Cruz, G. and 
Vazquez-Prado, J. (2011). Regulation of mTORC1 Complex Assembly and Signaling by 
GRp58/ERp57. Molecular and Cellular Biology, 31(8), 1657-1671.  
Ruddock, L., Hirst, T. and Freedman, R. (1996). pH-dependence of the dithiol-oxidizing activity of 
DsbA (a periplasmic protein thiol:disulphide oxidoreductase) and protein disulphide-isomerase: 
studies with a novel simple peptide substrate. Biochemical Journal, 315(3), 1001-1005.  
Russell, S., Ruddock, L., Salo, K., Oliver, J., Roebuck, Q., Llewellyn, D., Roderick, H., Koivunen, P., 
Myllyharju, J. and High, S. (2004). The Primary Substrate Binding Site in the b′ Domain of ERp57 Is 
Adapted for Endoplasmic Reticulum Lectin Association. Journal of Biological Chemistry, 279(18), 
18861-18869.  
Schulman, S., Bendapudi, P., Sharda, A., Chen, V., Bellido-Martin, L., Jasuja, R., Furie, B., Flaumenhaft, 
R. and Furie, B. (2016). Extracellular Thiol Isomerases and Their Role in Thrombus Formation. 
Antioxidants & Redox Signaling, 24(1), 1-15.  
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7. Appendix 
The following pictures concern to the rights of figures 2 and 3, respectively. 
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